Trial · NCT01722331
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) | Tildrakizumab 200 mg (Part 1) | 62.3 | Percentage of Participants | ||
| Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) | Tildrakizumab 100 mg (Part 1) | 63.8 | Percentage of Participants | ||
| Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) | Placebo (Part 1) | 5.8 | Percentage of Participants | ||
| Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) | Tildrakizumab 200 mg (Part 1) | 59.1 | Percentage of Participants | ||
| Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) | Tildrakizumab 100 mg (Part 1) | 57.9 | Percentage of Participants | ||
| Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) | Placebo (Part 1) | 7.1 | Percentage of Participants | ||
| Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) | Tildrakizumab 200 mg (Part 1) | 130 | Participants | ||
| Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) | Tildrakizumab 100 mg (Part 1) | 146 | Participants | ||
| Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) | Placebo (Part 1) | 74 | Participants | ||
| Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) | Tildrakizumab 200 mg (Part 1) | 5 | Participants | ||
| Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) | Tildrakizumab 100 mg (Part 1) | 0 | Participants | ||
| Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) | Placebo (Part 1) | 1 | Participants | ||
| Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) | Tildrakizumab 200 mg (Part 1) | 2 | Participants | ||
| Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) | Tildrakizumab 100 mg (Part 1) | 0 | Participants | ||
| Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) | Placebo (Part 1) | 0 | Participants | ||
| Percentage of Participants With PASI-90 Response At Week 12 | Tildrakizumab 200 mg (Part 1) | 35.4 | Percentage of participants | ||
| Percentage of Participants With PASI-90 Response At Week 12 | Tildrakizumab 100 mg (Part 1) | 34.6 | Percentage of participants | ||
| Percentage of Participants With PASI-90 Response At Week 12 | Placebo (Part 1) | 2.6 | Percentage of participants | ||
| Percentage of Participants With PASI-100 Response at Week 12 | Tildrakizumab 200 mg (Part 1) | 14.0 | Percentage of participants | ||
| Percentage of Participants With PASI-100 Response at Week 12 | Tildrakizumab 100 mg (Part 1) | 13.9 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01722331/results